For how we live.
In a 142-patient phase 3 trial, 37% reached complete remission on the antibody obinutuzumab versus 6% on tacrolimus at two years. A key kidney-function endpoint was not met, tempering the result.
One study maps the five barriers that delayed life-saving crush-syndrome care; another finds the long-term health burden of the disaster fell hardest on young women.
A regional review finds heat-protection for outdoor workers still leans on limiting work hours, while separate papers link chronic heat exposure among Gulf migrant labourers to a non-traditional form of kidney disease.
Two peer-reviewed studies chart the toll: among 122 Khartoum dialysis patients followed for up to 18 months, 53% survived, and those who stayed in the capital fared worst.
Sparsentan cut proteinuria nearly in half in the DUPLEX trial's FSGS patients. Its effect on the eGFR measure that tracks actual kidney function decline was smaller, and comes with a liver-monitoring requirement.